The Lancet vs NEJM: Which Should You Submit To?

NEJM and The Lancet are the two most-cited clinical medicine journals on the planet. NEJM's IF is 78.5 and The Lancet's is 88.5. Both are effectively impossible to publish in for most researchers. Both should be on your list if your clinical research is genuinely practice-changing. The question isn't which is better - it's which is the right fit for your specific paper. And the answer is less obvious than most researchers assume.

The Lancet's IF (88.5) is higher than NEJM's (78.5), which surprises many researchers. This partly reflects The Lancet's broader scope: global health and policy papers accumulate citations across a wider range of disciplines. NEJM remains the journal most US clinicians and promotion committees treat as the gold standard for clinical trials. In practice, publishing in either journal is a career-defining achievement.

This is what actually determines which journal fits your paper.NEJM is primarily a journal for US clinical practice. Its editorial priorities reflect what changes patient management in the United States - RCTs with strong external validity for US patient populations, studies that challenge or confirm existing US clinical guidelines, and original research with direct implications for American clinical practice. International studies are published, but US practitioners and their patients are the primary audience the editorial team has in mind.NEJM's medical culture is also more conservative. The journal prizes rigor and caution over novelty. A well-designed RCT with a null result that definitively resolves a clinical question gets serious consideration. A novel finding that hasn't been replicated yet faces more skepticism.The Lancet has a fundamentally different orientation. It was founded in London, is owned by Elsevier (a Dutch company), and has a genuinely global editorial perspective. The Lancet has historically been more willing to publish research from low- and middle-income countries, research addressing disease burdens that are global rather than primarily Western, and studies whose primary relevance is to healthcare systems outside the US.The Lancet is also more willing to publish studies that challenge existing practice based on observational or quasi-experimental designs, particularly in global health and public health contexts where RCTs are not always feasible or ethical.

NEJM does better for:- Phase 3 RCTs with large US patient populations- Studies with direct implications for US clinical guidelines- Research that changes standard of care across a broad US patient population- Negative trials that definitively resolve a clinical question- Clinical observations with immediate US practice implicationsThe Lancet does better for:- Multi-country RCTs with global scope- Global health studies and disease burden research- Research from LMIC settings that addresses diseases with primary global burden- Systematic reviews and meta-analyses with global scope- Public health policy-relevant research- Studies that challenge established practice based on observational designs- Research addressing infectious disease in global contextThe Lancet's specialty journal family is also worth noting. If your research is in oncology, neurology, psychiatry, infectious disease, respiratory medicine, rheumatology, or digital health, the relevant Lancet specialty journal has lower rejection rates than the flagship and publishes work at the specialty level that the flagship wouldn't.

Researchers based outside the US who are submitting a study conducted in their country's healthcare system face a real strategic question.NEJM's US-centered orientation doesn't mean it won't publish international research - it has published landmark trials from Europe, Australia, and Asia - but the editorial bar is that the finding must matter to US clinicians and patients. A trial conducted in a single European healthcare system that addresses a practice question without clear US relevance faces a harder desk review at NEJM than at The Lancet.The Lancet, conversely, actively cultivates research from non-Western settings. Founding Lancet editor Richard Horton's explicit commitment to global health equity has shaped The Lancet's editorial priorities for decades. A trial conducted across African healthcare systems addressing malaria treatment, HIV management, or maternal health will get serious attention at The Lancet that it wouldn't at NEJM.

For US-based trials with a US patient population and US practice implications: NEJM first. The IF advantage is real, and if the paper is appropriate for either journal, NEJM's IF will matter for citation velocity and career visibility.For international or multi-country trials: The Lancet first.For global health research: The Lancet, without question.For research at the specialty level (oncology, neurology, etc.): consider the relevant Lancet specialty journal alongside the flagship.For negative trials that definitively resolve a practice question: NEJM has a history of valuing well-designed null results. The Lancet does too, but NEJM has published some of the most-cited negative trials in clinical medicine.

NEJM and The Lancet both require cover letters, structured abstracts, and declarations. The meaningful difference is The Lancet's mandatory Research in Context panel.

The Research in Context panel has three required sections: "Evidence before this study" (what a systematic search of prior literature shows), "Added value of this study" (what this paper specifically contributes), and "Implications of all the available evidence" (what should change now). This panel is unique to The Lancet and it is read closely. A weak or generic Research in Context panel, particularly one that just paraphrases the abstract, is a common early trigger for desk rejection.

NEJM does not have an equivalent panel. Instead, NEJM's cover letter carries more weight than at most journals. The cover letter must lead with the practice change in plain language, identify the specific clinical population, and make the case for broad consequence without relying on prestige framing. Authors who open the cover letter with "We wish to submit our manuscript to NEJM" rather than the clinical consequence are signaling that the paper may not have cleared the internal consequence test.

Knowing which document matters most at each journal shapes preparation time. At The Lancet, invest time in the Research in Context panel. At NEJM, invest time in the cover letter's first paragraph.

A desk rejection from either flagship is not the end of the paper. It is a scope signal.

If NEJM rejects for being too geographically narrow, the same paper is often a strong candidate for The Lancet or JAMA. If The Lancet rejects for lacking global breadth, the paper likely belongs in a Lancet specialty journal (Lancet Oncology, Lancet Neurology, Lancet Infectious Diseases) or JAMA. Read the rejection letter carefully. Editors at both journals will sometimes indicate whether the scope problem is "not for any flagship" or "not for this specific flagship."

The transfer option also exists. The Lancet offers direct transfer to specialty titles, and the editorial assessment often carries over. This can save two to four weeks compared to restarting the process fresh. NEJM does not have the same family cascade, so a NEJM rejection typically means restarting at the next journal on your list.

Both journals desk-reject around 80-85% of submissions. What gets turned back without review:- Studies that don't meet the threshold of "practice-changing." Both journals define this strictly: the finding has to change what clinicians do with their patients across a large population.- Phase 2 trials without exceptional biological or clinical novelty- Single-center studies (with rare exceptions for extraordinary findings)- Studies with primary relevance to a niche subspecialty population- Observational studies without exceptional scale, rigor, or novelty- Clinical science that belongs in a specialty journal (e.g., a well-designed cardiac imaging study belongs at Circulation or JACC, not NEJM or Lancet)The cover letter for both journals should lead with the practice change: "This trial changes [X] recommendation for [Y patient population] because [finding Z]." Not "this study investigates" or "this trial aims to clarify." The conclusion, in one sentence, in paragraph one.

• the paper is a definitive clinical trial or general-medicine result with immediate US practice consequences
• the comparator and endpoint package are strong enough that the manuscript can survive aggressive clinical scrutiny
• the central message stays powerful even when global-health framing is stripped away

• the result matters across countries, health systems, or policy settings instead of mainly within US practice
• the paper gains strength from international relevance, population breadth, or public-health consequence
• the manuscript still reads like a flagship clinical story even if NEJM would consider it too geographically narrow

Is NEJM better than The Lancet?The Lancet actually has the higher impact factor (88.5 vs NEJM's 78.5), but "better" depends on your research. For US clinical trials, NEJM is the stronger fit. For international and global health research, The Lancet is often the better choice. Both are the most prestigious clinical journals in the world.What's the acceptance rate at NEJM vs The Lancet?NEJM accepts fewer than 5% of all submitted manuscripts. The Lancet accepts around 5-8%. Both desk-reject approximately 80-85% of submissions before external peer review. If your paper reaches full peer review at either journal, your odds improve substantially.Can the same paper be published in both NEJM and The Lancet?No. Once submitted, the paper is under exclusive review by one journal. Simultaneous submission to competing journals is an ethical violation and grounds for rejection or retraction.Does The Lancet have a specialty journal family?Yes. The Lancet family includes Lancet Oncology (IF ~41), Lancet Neurology (IF ~46), Lancet Psychiatry, Lancet Infectious Diseases, Lancet Respiratory Medicine, Lancet Digital Health, Lancet Rheumatology, and others. These specialty journals have lower rejection rates than the flagship and are appropriate for high-quality specialty research.Should I submit to NEJM or Lancet before specialty journals?Yes, if the work genuinely meets their threshold. Submit to the highest appropriate journal first - you can always work down the prestige ladder, but you can't work up after publication. If NEJM or Lancet reject with feedback that the work is strong but better suited for a specialty audience, that's useful information for your next target.

Choose The Lancet (IF 88.5, JCI 23.28, Q1 rank 1/332) if:

• Your trial enrolled patients across multiple countries or health systems
• The primary relevance is global health, public health policy, or disease burden outside the US
• Your study addresses health equity, LMIC populations, or infectious disease with worldwide impact
• The narrative is stronger when framed as an international story rather than a US practice change

Choose NEJM (IF 78.5, JCI 23.30, Q1 rank 2/332) if:

• Your trial was designed to change US clinical guidelines or standard of care
• The patient population is primarily US-based or the finding has immediate US practice implications
• You have a definitive negative trial that resolves a longstanding US clinical question
• The study's strength comes from rigorous design and clear US practice consequences rather than geographic breadth

Still unsure? Ask yourself: does the result change what clinicians do in Boston, or what clinicians do in Nairobi? Both journals desk-reject 80-85% of submissions, so fit matters more than preference. Submitting to the wrong flagship wastes months.

Last verified: JCR 2024 for both journals (Lancet IF 88.5, JCI 23.28, Q1 rank 1/332; NEJM IF 78.5, JCI 23.30, Q1 rank 2/332).